Synlogic, Inc.

Good morning. Welcome to Synlogic's third quarter 2020 conference call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded. I would now like to turn the call over to Daniel Roseanne, Head of Corporate Finance and Investor Relations. Please proceed.

Thank you, Operator. Good morning, and thanks for joining us on today's conference call. This morning, we issued a press release which outlines our third quarter 2020 financial results and several other topics that we plan to discuss today. The release is available on the investor section of our website at SynlogicTX.com. Joining me on this call are Dr. Aoife Brennan, President and Chief Executive Officer, Greg Beloff, Interim Chief Financial Officer, and Dr. Richard Rees, Chief Medical Officer. Also joining us is Dr. David Hava, newly appointed Chief Scientific Officer. During the call, Aoife will provide a brief outline of third quarter highlights and recent progress. Greg will summarize our financial results for the quarter, and Richard will provide an update on our metabolic portfolio. Following our prepared remarks, we will open the call for your questions. As we begin, I'd like to remind everyone that comments today may include forward-looking statements made under the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date hereof and are subject to numerous factors, assumptions, risks, and uncertainties which change over time. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including those described under the heading forward-looking statements in our press release today or under the heading risk factors in our most recent 10-K filings or later filings with the SEC. So, logic cautions you not to place undue reliance on any forward-looking statement. And now, I'd like to turn the call over to Aoife.

Thanks, Dan. Good morning, everyone, and thank you for joining us. I am thrilled today to share with you our third quarter 2020 financial results and highlight recent achievements, including our newest candidate in enteric hyperoxaluria entering the clinic this week ahead of schedule and the initiation of our PKU Symphony I Phase II study. To me, autumn colors and back to school always feel like the real start of the new year. And that has been especially true for us here at Synlogic. We've rapidly moved our clinical portfolio forward over the past nine months. And now we are gaining momentum as we head into one of the most data-rich periods in our history. Over the past few years, we have built the premier synthetic biology platform. and today we're laser-focused on establishing that platform as one that patients can rely on for life-changing treatments. I know that we have the team, technology, and portfolio to succeed, and I want to start today by discussing our team. Our recent research engine is one of the most productive among small biotechs, bringing now four INDs into the clinic in short order. Each one of those INDs has come more rapidly than the one before. Yet, there is so much more we can do. Each day, there is even more breaking science on the power of bacterial therapeutics to change the course of human disease, something that Simlogic has realized and worked towards since day one. We continue to execute strongly across metabolic and immunomodulation programs. bringing the transformative power of synthetic biology to medicine. That is why I'm pleased to welcome Dr. Dave Hava, rounding out our leadership team as Chief Scientific Officer. Dave is an experienced drug hunter who has brought multiple programs from ideation into and through the clinic and has led numerous successful partnerships. He is a microbiologist, who was doing synthetic biology long before the field adopted that label. We look forward to Dave tuning our already prolific research engine. Dave, would you like to say a few words?